Comorbidity and survival of Danish patients with colon and rectal cancer from 2000–2011: a population-based cohort study

Eva Bjerre Ostenfeld¹,² Mette Nørgaard¹ Reimår Wernich Thomsen¹ Lene Hjerrild Iversen⁴ Jacob Bonde Jacobsen¹ Mette Søgaard¹

¹Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; ²Department of Surgery A, Aalborg University Hospital, Aalborg, Denmark; ³Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark

Objective: To evaluate recent trends in the prevalence and impact of comorbidity on colorectal cancer (CRC) survival in the Central Region of Denmark.

Material and methods: Using the Danish National Registry of Patients, we identified 5,777 and 2,964 patients with a primary colon or rectal cancer, respectively, from 2000 through 2011. We estimated survival according to Charlson Comorbidity Index scores and computed mortality rate ratios (MRRs) using Cox proportional hazard regression analysis, adjusting for age and sex.

Results: More than one-third of CRC patients had comorbidity at diagnosis. During the study period, 1-year survival increased substantially in colon cancer patients with Charlson score 0 (72% to 80%) and modestly for Charlson score 3+ patients (43% to 46%). Using colon cancer patients with Charlson score 0 as reference, adjusted 1-year MRRs in patients with Charlson score 3+ were 2.19 (95% confidence interval [CI]: 1.57–3.05) in 2000–2002 and 2.56 (95% CI: 1.96–3.35) in 2009–2011. One-year survival after rectal cancer improved from 81% to 87% in patients with Charlson score 0 and from 56% to 60% in Charlson score 3+. Corresponding MRRs in patients with Charlson score 3+ were 2.21 (95% CI: 1.33–3.68) in 2000–2002 and 3.09 (95% CI: 1.91–5.00) in 2009–2011 using Charlson score 0 as reference. Five-year MRRs did not differ substantially from 1-year MRRs.

Conclusion: Comorbidity was common among CRC patients and was associated with poorer prognosis. We observed improved survival from 2000 to 2011 for all comorbidity levels, with least improvement for colon cancer patients with comorbid conditions.

Keywords: colon, rectal, neoplasms, comorbidity, survival, epidemiology, Denmark

Background

Worldwide, colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death.¹ CRC incidence increases sharply with age² as do the prevalence of chronic diseases.³ Consequently, a large proportion of CRC patients suffer from one or more comorbid conditions at the time of their cancer diagnosis⁴⁻⁶ which may affect their diagnostic work up, treatment options, and prognosis.⁷⁻⁸ Several studies indicate that CRC patients with coexisting diseases have a poorer survival compared to those without.⁴⁻⁶,⁷⁻¹⁰

Due to population aging, the proportion of elderly cancer patients is increasing.¹¹ The challenge in cancer treatment that comorbidity, physiologic, and functional frailty in these aging patients may pose will thus increase in the future.¹²

Monitoring trends in CRC survival is urgent for optimizing clinical cancer care and outcomes. Despite knowledge that coexisting diseases affect CRC prognosis, only
a few studies incorporate comorbidity in survival trends.\textsuperscript{3,5} Previous Danish research reported improved 1- and 5-year survival for colon cancer patients with Charlson score 3+ during 1995–2006, whereas for rectal cancer patients with similar Charlson scores, 1-year survival was stable.\textsuperscript{6} In the present population-based study we examine the most recent changes in the prevalence and the impact of comorbidity on survival and mortality in a cohort of CRC patients diagnosed during 2000–2011 using Danish medical registry data.

Material and methods

Study population

We conducted this population-based cohort study in the Central Denmark region, which has 1.2 million inhabitants.\textsuperscript{13} The Danish National Health Service provides universal, tax-supported health care, guaranteeing unfettered access to general practitioners and hospitals and partial reimbursement for prescribed drugs. Accurate and unambiguous linkage of all registries at the individual level is possible in Denmark by means of the unique personal registry number assigned to each Danish citizen at birth or immigration.

Identification of patients with CRC

We identified all patients with a diagnosis of colon cancer (International Classification of Diseases [ICD]-8 code 153-154.09 and ICD-10 code C18-19) and rectal cancer (ICD-8 code 154.10-154.29 and ICD-10 code C20) from January 1, 1995 through December 31, 2011, using the Danish National Registry of Patients (NRP). The NRP contains records of all non-psychiatric hospital admissions since 1977 and outpatient hospital visits since 1995. Information includes the patient’s civil registration number, dates of admission and discharge, and up to 20 discharge diagnoses, coded by physicians according to the 8th revision of the International Classification of Diseases until the end of 1993, and the 10th revision thereafter.\textsuperscript{14} Patients with a previous diagnosis of colon or rectal cancer were excluded from the cohort.

Comorbidity at diagnosis

From the NRP, we obtained information on pre-existing comorbidity 10 years prior to the date of CRC diagnosis using the Charlson Index. This index comprises 19 disease categories each assigned between one and six points according to the adjusted risk of 1-year mortality.\textsuperscript{15,16} We used the sum of these points (ie, the Charlson score) to categorize patients. CRC diagnoses were excluded when we computed the Charlson score, as were all cancer diagnoses within 60 days before the CRC cancer diagnosis, in order to eliminate possible nonspecific cancer diagnoses related to the CRC cancer diagnosis. We grouped patients according to their level of comorbidity: (1) Charlson score = 0; (2) Charlson score = 1–2; and (3) Charlson score 3+.

Vital status

We linked members of the study cohort via their personal registry number to the Danish Civil Registration System to obtain vital status.\textsuperscript{17} This registry has recorded all changes in vital status and migration for the entire Danish population since 1968, with daily electronic updates. Follow-up was through patient date of death or emigration or December 31, 2011, whichever occurred first.

Statistical analysis

We computed the prevalence of comorbidity in CRC patients during four 3-year study periods: 2000–2002, 2003–2005, 2006–2008, and 2009–2011. We constructed Kaplan–Meier survival curves for CRC patients according to Charlson score and study periods. Cox proportional hazards regression was used to compute 1- and 5-year crude and age- and sex-adjusted hazard ratios as a measure of relative mortality to assess the association of comorbidity with mortality using the Charlson score of 0 as a reference in each time period. In the latter periods, we estimated 1- and 5-year survival using a hybrid analysis in which survival was estimated using the survival experience of patients in the previous periods.\textsuperscript{18} CRC stage and treatment was considered as a causal intermediate and therefore not included in the analyses.\textsuperscript{19} All analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC, USA). The study was approved by the Danish Data Protection Agency (record number 2006-53-1346).

Results

Colon cancer

Prevalence of comorbidity

A total of 5,777 patients were diagnosed with colon cancer during 2000–2011 of which 48% were men (Table 1). For both sexes, colon cancer incidence increased over time. The prevalence of patients with Charlson score 0 decreased from 66% to 62% during the time period, with a corresponding increase in the prevalence of patients with Charlson score 3+ (4%). Overall median age at diagnosis was 72 years and did not change during the study period. Patients with Charlson score 0 had the lowest median age which decreased from 71 to 69 years during the study period. Accordingly, median age increased for patients with a Charlson score 1–2 (from 75 to 76 years) and Charlson score 3+ (from 74 to 78 years).
**Table 1** Characteristics of colon and rectal cancer patients in the Central Region of Denmark 2000–2011

| Characteristics | Year of diagnosis | Total |
|-----------------|-------------------|-------|
|                 | 2000–2002 | 2003–2005 | 2006–2008 | 2009–2011 |
| **Colon cancer** | | | | |
| **Sex** | | | | |
| Male (%) | 629 (49) | 616 (46) | 759 (50) | 790 (49) | 2794 (48) |
| Female (%) | 663 (51) | 731 (54) | 769 (50) | 820 (51) | 2983 (52) |
| Median age (years) | 72 | 73 | 73 | 72 | |
| **Comorbidity** | | | | |
| Charlson score 0 (%) | 856 (66) | 841 (62) | 894 (59) | 992 (62) | 3583 (62) |
| Charlson score 1–2 (%) | 362 (28) | 391 (29) | 475 (31) | 451 (28) | 1679 (29) |
| Charlson score 3+ (%) | 74 (6) | 115 (9) | 159 (10) | 167 (10) | 515 (9) |
| Median age (years) | | | | |
| Charlson score 0 (%) | 71 | 70 | 69 | 69 | |
| Charlson score 1–2 (%) | 75 | 75 | 76 | 76 | |
| Charlson score 3+ (%) | 74 | 78 | 77 | 78 | |
| **Rectal cancer** | | | | |
| **Sex** | | | | |
| Male (%) | 388 (54) | 380 (60) | 435 (57) | 468 (55) | 1671 (56) |
| Female (%) | 328 (46) | 255 (40) | 325 (43) | 385 (45) | 1293 (44) |
| Median age (years) | 70 | 69 | 68 | 69 | |
| **Comorbidity** | | | | |
| Charlson score 0 (%) | 512 (72) | 427 (67) | 499 (66) | 567 (66) | 2005 (68) |
| Charlson score 1–2 (%) | 163 (23) | 167 (26) | 194 (26) | 221 (26) | 745 (25) |
| Charlson score 3+ (%) | 41 (6) | 41 (6) | 67 (9) | 65 (8) | 214 (7) |
| Median age (years) | | | | |
| Charlson score 0 (%) | 68 | 67 | 64 | 67 | |
| Charlson score 1–2 (%) | 74 | 74 | 74 | 73 | |
| Charlson score 3+ (%) | 76 | 74 | 74 | 77 | |

**Survival**

Overall 1-year survival gradually improved from 68% (95% confidence interval [CI]: 65%–70%) in 2000–2002 to 73% (95% CI: 71%–75%) in 2009–2011 corresponding to an adjusted mortality rate ratio (MRR) of 0.74 (95% CI: 0.64–0.85) in 2009–2011 using 2000–2002 as a reference (Table 2). Accordingly, the overall 5-year survival improved from 39% (95% CI: 37%–42%) to a predicted survival of 46% (95% CI: 43%–48%) for those diagnosed in 2009–2011, corresponding to a 5-year adjusted MRR of 0.76 (95% CI: 0.69–0.84) compared to 2000–2002.

Figure 1 shows survival curves for colon cancer patients within each comorbidity group according to time period. Survival among patients with Charlson score 0 improved during the study period while the survival remained virtually unchanged for patients with Charlson score 1–2 diagnosed from 2003–2005 onwards (Figure 1A and B). In patients with Charlson score 3+, survival peaked in 2003–2005, but beyond 1-year of follow-up the predicted survival in the 2009–2011 period was even poorer than among patients diagnosed in 2003–2005 and 2006–2008 (Figure 1C).

Across all time periods, absolute survival decreased with increasing Charlson score and 5-year absolute survival among patients with Charlson scores 3+ was approximately half of that for patients with Charlson score 0 (Table 3). During the study period, survival improved in all comorbidity groups. From 2000–2002 to 2009–2011, 1-year survival improved among patients with Charlson score 0 (72% [95% CI: 69%–75%] to 80% [95% CI: 77%–82%]) as did 5-year survival (44% [95% CI: 41%–47%] to predicted 53% [95% CI: 50%–56%]). Similarly, 1- and 5-year survival improved among patients with Charlson score 1–2 and 3+ from 2000–2002 to 2009–2011, mainly due to substantial improvement from 2000–2002 to 2003–2005. Thus, from the period 2003–2005 on, survival appeared to stabilize in these patients. We observed that patients with comorbidity had poorer survival than those with no comorbidity in each diagnostic period (Table 3). Also, we noted a tendency that the relative mortality increased slightly from the first to the last time periods, although differences were not statistically significant. One-year adjusted MRRs for patients with Charlson score 1–2 ranged from 1.19 (95% CI: 0.96–1.47) to 1.43 (95% CI: 1.14–1.80), and 5-year adjusted MRRs ranged from 1.20 (95% CI: 1.02–1.40) to 1.26 (95% CI: 1.08–1.46), using patients with Charlson score 0 as a reference.
Corresponding 1- and 5-year adjusted MRRs for patients with Charlson score 3+, ranged from 2.19 (95% CI: 1.57–3.05) to 2.56 (95% CI: 1.96–3.35) and 2.10 (95% CI: 1.61–2.74) to 2.30 (95% CI: 1.89–2.80), respectively.

Rectal cancer
Prevalence of comorbidity
Of the 2,964 rectal cancer patients diagnosed during the study period, 56% were men (Table 1). Incident rectal cancer increased only slightly over time. Patients with Charlson score 0 accounted for 72% in 2000–2002 and 66% in 2009–2011 with corresponding increases in the prevalence of patients with Charlson score 1–2 (3%) and 3+ (2%). Overall median age at diagnosis was 69 years. Patients with Charlson score 0 had the lowest median age and only a minor decrease was observed over time (from 68 to 67 years), whereas the median age increased slightly for patients with Charlson score 3+ (from 76 to 77 years).

Survival
Overall 1-year survival after rectal cancer improved from 77% (95% CI: 74%–80%) in 2000–2002 to 80% (95% CI: 77%–82%) in 2009–2011 with a corresponding adjusted MRR of 0.85 (95% CI: 0.68–1.05) using 2000–2002 as a reference (Table 2). Accordingly, the overall 5-year survival improved from 46% (95% CI: 42%–50%) to a predicted 49% (95% CI: 45%–52%) during the study period, corresponding to an adjusted MRR of 0.91 (95% CI: 0.79–1.05) in 2009–2011 as compared to 2000–2002.

Survival improved slightly within each comorbidity level during the study period, although patients with Charlson score 3+ had a poorer 1-year survival in the 2009–2011 period compared to the previous calendar period (Figure 2A–C).

As for colon cancer, survival after rectal cancer decreased with the burden of comorbidity in all diagnostic periods, in particular the 5-year survival (Table 4). For patients with Charlson score 3+, 5-year survival was less than half of that for patients with Charlson score 0. During the 2000–2011 period survival improved in all comorbidity groups, although for patients with Charlson score 3+ the 5-year survival was almost unchanged from 2003 throughout the study period.

Compared to patients with Charlson score 0 the MRRs increased with increasing level of comorbidity in each calendar period (Table 4). One- and 5-year adjusted MRRs were almost unchanged from the first to the last time periods.

Discussion
In this population-based study, more than one-third of the CRC patients had documented comorbid conditions according to the Charlson Index and the overall prevalence of
Figure 1 Kaplan–Meier curves for colon cancer patients in the Central Region of Denmark for four diagnostic periods for (A) Charlson score = 0, (B) Charlson score = 1–2, and (C) Charlson score = 3+. 
Comorbidity increased slightly over the 12-year study period. Comorbidity was a strong negative prognostic factor even after adjusting for age. From 2000–2002 to 2009–2011, CRC survival improved within each level of comorbidity, mainly due to an apparent large improvement until 2003–2005, after which survival stagnated among colon cancer patients with comorbid conditions, from 2003 through 2011. During this time period, the relative mortality was almost unchanged for rectal cancer patients, whereas for colon cancer patients the relative mortality seemed to increase weakly.

The increasing prevalence of comorbidity among patients with CRC over the study period may be attributable to demographic changes in terms of population aging or to closer medical follow-up of patients with chronic conditions leading to the detection of more CRC cases. Also, the introduction of an accounting method based on Diagnosis Related Groups in 2000 by the Danish health care authorities may have led to more complete recording of concurrent diseases in addition to the main condition. Still, the prevalence of comorbidity in CRC patients was higher in a recent Dutch

Table 3 One-year and 5-year survival and relative mortality after colon cancer according to comorbidity level for each diagnostic period in the Central Region of Denmark 2000–2011

| Charlson score | 0 | 1–2 | 3+ |
|----------------|---|-----|----|
| **2000–2002**  |   |     |    |
| Number of patients | 856 | 362 | 74 |
| 1-year Survival (%) | 72% (69%–75%) | 63% (58%–68%) | 43% (32%–54%) |
| MRR crude | 1 (reference) | 1.41 (1.14–1.75) | 2.71 (1.95–3.76) |
| MRR adjusted | 1 (reference) | 1.19 (0.96–1.47) | 2.19 (1.57–3.05) |
| 5-year Survival (%) | 44% (41%–47%) | 33% (29%–38%) | 15% (8%–24%) |
| MRR crude | 1 (reference) | 1.34 (1.15–1.56) | 2.46 (1.89–3.20) |
| MRR adjusted | 1 (reference) | 1.20 (1.02–1.40) | 2.10 (1.61–2.74) |
| **2003–2005**  |   |     |    |
| Number of patients | 841 | 391 | 115 |
| 1-year Survival (%) | 73% (70%–76%) | 66% (62%–71%) | 55% (45%–63%) |
| MRR crude | 1 (reference) | 1.32 (1.06–1.63) | 1.93 (1.43–2.60) |
| MRR adjusted | 1 (reference) | 1.17 (0.94–1.46) | 1.61 (1.19–2.19) |
| 5-year Survival (%) | 48% (45%–51%) | 41% (36%–45%) | 28% (20%–36%) |
| MRR crude | 1 (reference) | 1.23 (1.05–1.44) | 1.79 (1.41–2.26) |
| MRR adjusted | 1 (reference) | 1.11 (0.95–1.31) | 1.54 (1.21–1.96) |
| **2006–2008**  |   |     |    |
| Number of patients | 894 | 475 | 159 |
| 1-year Survival (%) | 77% (74%–79%) | 68% (64%–72%) | 50% (42%–58%) |
| MRR crude | 1 (reference) | 1.45 (1.17–1.79) | 2.61 (2.02–3.38) |
| MRR adjusted | 1 (reference) | 1.25 (1.01–1.55) | 2.27 (1.74–2.95) |
| 5-year Survival (%) | 51% (48%–55%) | 41% (36%–45%) | 22% (16%–29%) |
| MRR crude | 1 (reference) | 1.36 (1.17–1.58) | 2.40 (1.94–2.96) |
| MRR adjusted | 1 (reference) | 1.20 (1.03–1.40) | 2.11 (1.72–2.59) |
| **2009–2011**  |   |     |    |
| Number of patients | 992 | 451 | 167 |
| 1-year Survival (%) | 80% (77%–82%) | 69% (64%–73%) | 46% (38%–54%) |
| MRR crude | 1 (reference) | 1.70 (1.36–2.12) | 3.31 (2.55–4.30) |
| MRR adjusted | 1 (reference) | 1.43 (1.14–1.80) | 2.56 (1.96–3.35) |
| 5-year Survival (%) | 53% (50%–56%) | 41% (36%–45%) | 19% (14%–25%) |
| MRR crude | 1 (reference) | 1.44 (1.24–1.68) | 2.78 (2.29–3.37) |
| MRR adjusted | 1 (reference) | 1.26 (1.08–1.46) | 2.30 (1.89–2.80) |

Notes: Figures in brackets represent 95% confidence intervals; MRRs according to comorbidity level using Charlson score 0 as reference, adjusted for age and sex; b predicted values.

Abbreviation: MMR, mortality rate ratio.
Figure 2 Kaplan–Meier curves for rectal cancer patients in the Central Region of Denmark for four diagnostic periods for (A) Charlson score = 0, (B) Charlson score = 1–2, and (C) Charlson score = 3+.
In agreement with previous research, we found that CRC patients with comorbidity had a poorer survival than those without comorbidity.\textsuperscript{4,6,8–10} Several mechanisms may explain the disparity in survival. First, severe comorbidity affects risk of mortality independent of the cancer, especially when the mortality burden of the cancer is low.\textsuperscript{20} Second, comorbidity may delay CRC diagnosis by masking symptoms of the cancer, leading to late stage disease and poor prognosis. However, closer medical follow-up of comorbid patients could also lead to cancer detection at earlier stages.\textsuperscript{21}

### Table 4 One-year and 5-year survival and relative mortality after rectal cancer according to comorbidity level for each diagnostic period in the Central Region of Denmark 2000–2011

|                         | Charlson score |       |       |       |       |       |       |       |       |       |
|-------------------------|----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|                         | 0              | 1–2   | 3+    |       |       |       |       |       |       |       |
| **2000–2002**           |                |       |       |       |       |       |       |       |       |       |
| Number of patients      | 512            | 163   | 41    |       |       |       |       |       |       |       |
| Survival (%)            | 81% (77%–84%)  | 69% (62%–76%) | 56% (40%–70%) |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.76 (1.25–2.47) | 2.73 (1.65–4.52) |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.46 (1.03–2.06) | 2.21 (1.33–3.68) |       |       |       |       |       |       |       |
| **5-year**              |                |       |       |       |       |       |       |       |       |       |
| Survival (%)            | 51% (47%–56%)  | 36% (29%–44%)  | 17% (8%–30%)   |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.58 (1.25–1.98) | 2.50 (1.74–3.57) |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.37 (1.09–1.73) | 2.00 (1.39–2.88) |       |       |       |       |       |       |       |
| **2003–2005**           |                |       |       |       |       |       |       |       |       |       |
| Number of patients      | 427            | 167   | 41    |       |       |       |       |       |       |       |
| Survival (%)            | 81% (77%–84%)  | 71% (63%–77%)  | 56% (40%–70%) |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.64 (1.15–2.34) | 2.74 (1.64–4.56) |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.25 (0.87–1.80) | 2.40 (1.43–4.02) |       |       |       |       |       |       |       |
| **5-year**              |                |       |       |       |       |       |       |       |       |       |
| Survival (%)            | 56% (51%–60%)  | 41% (33%–48%)  | 24% (13%–38%) |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.56 (1.22–1.99) | 2.46 (1.68–3.59) |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.27 (0.99–1.64) | 2.20 (1.50–3.23) |       |       |       |       |       |       |       |
| **2006–2008**           |                |       |       |       |       |       |       |       |       |       |
| Number of patients      | 499            | 194   | 67    |       |       |       |       |       |       |       |
| Survival (%)            | 84% (80%–87%)  | 76% (70%–82%)  | 61% (48%–72%) |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.52 (1.06–2.19) | 2.67 (1.72–4.15) |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.13 (0.77–1.64) | 1.95 (1.24–3.07) |       |       |       |       |       |       |       |
| **5-year**              |                |       |       |       |       |       |       |       |       |       |
| Survival (%)            | 54% (50%–58%)\textsuperscript{a} | 43% (36%–50%)\textsuperscript{a} | 21% (11%–33%)\textsuperscript{a} |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.40 (1.11–1.76)\textsuperscript{a} | 2.33 (1.71–3.17)\textsuperscript{a} |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.13 (0.89–1.44)\textsuperscript{a} | 1.87 (1.36–2.57)\textsuperscript{a} |       |       |       |       |       |       |       |
| **2009–2011**           |                |       |       |       |       |       |       |       |       |       |
| Number of patients      | 567            | 221   | 65    |       |       |       |       |       |       |       |
| Survival (%)            | 87% (83%–89%)  | 78% (71%–83%)  | 60% (46%–71%) |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.82 (1.25–2.67) | 3.96 (2.48–6.33) |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.51 (1.02–2.24) | 3.09 (1.91–5.00) |       |       |       |       |       |       |       |
| **5-year**              |                |       |       |       |       |       |       |       |       |       |
| Survival (%)            | 58% (53%–62%)\textsuperscript{a} | 44% (37%–51%)\textsuperscript{a} | 22% (12%–35%)\textsuperscript{a} |       |       |       |       |       |       |       |
| MRR crude               | I (reference)  | 1.55 (1.24–1.93)\textsuperscript{a} | 2.67 (1.94–3.66)\textsuperscript{a} |       |       |       |       |       |       |       |
| MRR adjusted\textsuperscript{a} | I (reference)  | 1.33 (1.05–1.67)\textsuperscript{a} | 2.24 (1.62–3.10)\textsuperscript{a} |       |       |       |       |       |       |       |

**Notes:** Figures in brackets represent 95% confidence intervals; \textsuperscript{a}MRRs according to comorbidity level with Charlson score 0 as reference, adjusted for age and sex; bpredicted estimates.

**Abbreviation:** MMR, mortality rate ratio.

The study by van Leersum et al\textsuperscript{5} than in our study. In that study, the proportion of CRC patients with comorbid conditions according to the Charlson Index increased from 47% in 1995 to 62% in 2010. However, their comorbidity data had been assessed in part from medical hospital records and also from referral letters from general practitioners. Because we used discharge diagnoses in the NRP, we had no information on chronic diseases treated solely at the general practitioners; eg, hypertension, diabetes and pulmonary diseases, which were the most frequent conditions in the Dutch study. In agreement with previous research, we found that CRC patients with comorbidity had a poorer survival than those without comorbidity.\textsuperscript{5,6,8–10} Several mechanisms may explain the disparity in survival. First, severe comorbidity affects risk of mortality independent of the cancer,\textsuperscript{a} especially when the mortality burden of the cancer is low.\textsuperscript{20} Second, comorbidity may delay CRC diagnosis by masking symptoms of the cancer, leading to late stage disease and poor prognosis. However, closer medical follow-up of comorbid patients could also lead to cancer detection at earlier stages.\textsuperscript{21}
Comorbidity and colorectal cancer survival

Third, treatment strategies may be influenced by the burden of comorbidity. Frail patients may undergo less extensive surgery, and it has been reported that CRC patients with concomitant diseases receive less adjuvant therapy compared with those without.\(^7,8,22\) Fourth, interaction between comorbidity and the cancer may accelerate the course of the cancer.\(^23\)

The overall survival from CRC improved in Denmark from 2000 through 2011. The current observations thus agree with previous trends,\(^4,24–28\) although most studies did not incorporate comorbidity in their analyses. We noted a stagnating survival among colon cancer patients with coexisting diseases from 2003 onward, which discords with concurrent improvements in rectal cancer as well as previous observations.\(^4\) However, this apparent stagnation may in part have been caused by substantial improvements in survival among comorbid patients in the period between 2003–2005. During the study period, the surgical treatment of CRC was gradually centralized,\(^27\) facilitating higher hospital procedure volume and probably higher surgeon case volume across all levels of comorbidities. Still, in the Region of Central Denmark, colon cancer is treated at more hospitals than rectal cancer.\(^3\) Moreover, only rectal cancer is included in multidisciplinary teams comprised of radiologists, pathologists, surgeons, and oncologists, which has the potential to improve the outcome.\(^28\) We can only speculate whether this disparity in the management of colon and rectal cancer diagnostics and treatment may contribute to the discrepancy in survival.

Strengths of our study include a population-based design within the setting of a uniformly organized health care system. Our cohort was well-defined by the use of computerized registries with complete follow-up.\(^14,17,29\) Our study also had limitations; for instance, we used the Charlson Index to measure comorbidity, which has been tested reliable and valid.\(^16,30\) The positive predictive value of the NRP coding of the Charlson conditions has been demonstrated consistently high.\(^31\) However, the Charlson Index does not make allowance for the severity of the diseases. Thus, patients with identical scores may differ substantially in their functional impairment, which could influence mortality.\(^32\)

We lacked data on cancer stage, which might have been unevenly distributed among the comorbidity groups. Likewise, we lacked data on treatment, which could conceivably vary with the burden of comorbidity.\(^33\) Although both stage and treatment are prognostically important factors, they are causal intermediates and should not be adjusted for in the analyses. Moreover, according to the Danish Colorectal Cancer Group database, the stage distribution among CRC patients has not changed substantially between 2001 and 2011.\(^2\) Therefore, improvements in survival are less likely to stem from diagnosis at earlier stages over time. Also, we had no data on tumor histopathology. However, to our knowledge, there is no evidence of an association between comorbidity and tumor morphology, such as histologic subtype or grade. Morphology, therefore, should not bias our estimates. From the registries we had no information on structural factors, eg, increased hospital volume and population aging and potential confounders, such as smoking, alcohol consumption, and obesity. Finally, we only examined all-cause mortality and not disease-specific mortality. Nonetheless, given the difficulty of disentangling whether CRC itself, cancer complications, or underlying comorbidity contributed to mortality, we conclude that all-cause mortality is a valid measure.

In conclusion, we found that comorbidity was present in more than one-third of CRC patients and had a substantial negative impact on prognosis. Despite improved overall survival during 2000–2002 to 2009–2011 period, survival improvement was least in colon cancer patients with comorbid conditions. Due to an increasing proportion of elderly (comorbid) cancer patients, our findings warrant clinical and public attention.

Acknowledgments

Cancer analyses in the Central Denmark Region were conducted as part of the AUDEO (Aarhus University Disease Epidemiology and Outcomes) Project at the Department of Clinical Epidemiology, Aarhus University Hospital.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
2. Danish Colorectal Cancer Group. Nationwide database of colorectal cancer analyses in the Central Denmark Region were conducted as part of the AUDEO (Aarhus University Disease Epidemiology and Outcomes) Project at the Department of Clinical Epidemiology, Aarhus University Hospital.

[3. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67(2):124–132.
4. Iversen LH, Nørgaard M, Jacobsen J, Laurberg S, Sørensen HT. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006 – a population-based cohort study. Dis Colon Rectum. 2009;52(1):71–78.
5. van Leersum NJ, Janssen-Heijnen ML, Wouters MW, et al. Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995–2010. Int J Cancer. 2013;132(9):2157–2163.
6. Gross CP, Guo Z, McAvay GJ, Allore HG, Young M, Tinetti ME. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc. 2006;54(12):1898–1904.]
7. Chen RC, Roeyte TJ, Extermann M, Reeve BB. Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol. 2012;22(4):265–271.

8. Lemmens VE, Janssens-Heijnen ML, Verheij CJ, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92(5):615–623.

9. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer. 2009;9:116.

10. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82(11):2123–2134.

11. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31(2):128–136.

12. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237.

13. Population at the first day of the quarter by municipality, sex, age, marital status, ancestry, country of origin and citizenship – StatBank Denmark – data and statistics Available from: http://www.statistikbanken.dk/statbank5a/SelectVarVal/Define.asp?MainTable=FOLK1&PLanguage=1&PXSID=0&kwsid=cfree. Accessed December 12, 2012.

14. Lyne E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(Suppl 7):30–33.

15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.

16. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. The Danish Civil Registration System. Scand J Public Health Regist. 2003;56(3):221–229.

17. Pedersen CB. The Danish Civil Registration System. Scand J Public Health Regist. 2003;56(3):221–229.

18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.

19. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. The Danish Civil Registration System. Scand J Public Health Regist. 2003;56(3):221–229.

20. Pedersen CB. The Danish Civil Registration System. Scand J Public Health Regist. 2003;56(3):221–229.

21. Bremer H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer. 2004;40(16):2494–2501.

22. de Marco MF, Janssens-Heijnen ML, van der Heijden LH, Coebergh JW. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000;36(1):95–99.

23. van de Poll-Franse LV, Haak HR, Coebergh JW, Janssens-Heijnen ML, Lemmens VE. Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis. Diabetologia. 2012;55(8):2163–2172.

24. Coleman MP, Forman D, Bryant H, et al; ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–138.

25. Klint A, Engholm G, Storm HH, et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):578–607.

26. Ostenfeld EB, Erichsen R, Iversen LH, Gandrup P, Nørgaard M, Jacobsen J. Survival of patients with colon and rectal cancer in central and northern Denmark, 1998–2009. Clin Epidemiol. 2011;3 Suppl 1: 27–34.

27. Iversen LH. Aspects of Survival from Colorectal Cancer in Denmark [Doctoral thesis]. Aarhus: Faculty of Health Sciences, Aarhus University; 2011.

28. MacDermid E, Hooton G, MacDonald M, et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis. 2009;11(3):291–295.

29. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010;2:273–279.

30. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003;56(3):221–229.

31. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.

32. Wedding U, Röhrig B, Klippstein A, Pientka L, Höffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol. 2007;133(12): 945–950.

33. van Steenberghe LN, Elferink MA, Krijnen P, et al; Working Group Output of The Netherlands Cancer Registry. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006. Ann Oncol. 2010;21(11):2206–2212.